PMID- 37691972
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230913
IS  - 2253-5969 (Print)
IS  - 2253-5969 (Electronic)
IS  - 2253-5969 (Linking)
VI  - 10
DP  - 2023
TI  - Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the 
      Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study.
PG  - 1435-1443
LID - 10.2147/JHC.S423684 [doi]
AB  - PURPOSE: In the study, patients with unresectable hepatocellular carcinoma (uHCC) 
      were treated with either transcatheter chemoembolization (TACE) combined with 
      lenvatinib and PD-(L)1 inhibitor (TACE-L-P) or TACE combined with lenvatinib 
      (TACE-L). We compared the efficacy and safety of TACE-L-P with TACE-L, and 
      analyzed factors affecting prognosis. MATERIALS AND METHODS: A total of 122 
      patients were treated with either TACE-L-P (n = 64) or TACE-L (n = 58), and their 
      data was collected and analyzed. We assessed tumor response, progression-free 
      survival (PFS), prognostic factors for PFS and adverse events (AEs) to compare 
      the efficacy and safety of TACE-L-P with TACE-L for patients with uHCC. RESULTS: 
      TACE-L-P group's patients had a better objective response rate (ORR) (57.8% vs 
      41.4%, P = 0.047) and a better disease control rate (93.7% vs 81%, P = 0.013), as 
      long as a longer median progression-free survival (PFS) (8 months vs 4.6 months, 
      HR: 0.461; 95% CI: [0.314-0.675]; P = 0.001) than TACE-L group's patients. 
      According to multivariate analysis, independent prognostic factors for PFS 
      included treatment option (TACE-L-P / TACE-L; RH = 0.461; 95% CI [0.314-0.675]; P 
      = 0.001), PVTT (Yes/No; RH =1 0.599;95% CI [1 0.095-2 0.336]; P=0 0.017), 
      extrahepatic metastasis (Yes/No; RH=1 0.847;95% CI [1 0.176 -2 0.909]; P=0 
      0.008). AEs in TACE-L-P group was similar with TACE-L group. CONCLUSION: TACE-L-P 
      has more promising clinical outcomes in patients with uHCC than TACE-L, and their 
      safety is similar.
CI  - (c) 2023 Yang et al.
FAU - Yang, Hui
AU  - Yang H
AUID- ORCID: 0009-0008-9003-1025
AD  - Department of Interventional Therapy, Ningbo NO.2 Hospital, Ningbo, Zhejiang, 
      People's Republic of China.
FAU - Yang, Tiequan
AU  - Yang T
AUID- ORCID: 0009-0001-2488-9532
AD  - Department of Interventional Therapy, Ningbo NO.2 Hospital, Ningbo, Zhejiang, 
      People's Republic of China.
FAU - Qiu, Guangpin
AU  - Qiu G
AUID- ORCID: 0009-0002-7097-4081
AD  - Department of Interventional Therapy, Ningbo NO.2 Hospital, Ningbo, Zhejiang, 
      People's Republic of China.
FAU - Liu, Jie
AU  - Liu J
AUID- ORCID: 0009-0001-0952-632X
AD  - Department of Interventional Therapy, Ningbo NO.2 Hospital, Ningbo, Zhejiang, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20230905
PL  - New Zealand
TA  - J Hepatocell Carcinoma
JT  - Journal of hepatocellular carcinoma
JID - 101674775
PMC - PMC10492540
OTO - NOTNLM
OT  - PD-(L)1 inhibitor
OT  - hepatocellular carcinoma
OT  - lenvatinib
OT  - transarterial chemoembolization
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/09/11 06:43
MHDA- 2023/09/11 06:44
PMCR- 2023/09/05
CRDT- 2023/09/11 04:30
PHST- 2023/06/12 00:00 [received]
PHST- 2023/08/30 00:00 [accepted]
PHST- 2023/09/11 06:44 [medline]
PHST- 2023/09/11 06:43 [pubmed]
PHST- 2023/09/11 04:30 [entrez]
PHST- 2023/09/05 00:00 [pmc-release]
AID - 423684 [pii]
AID - 10.2147/JHC.S423684 [doi]
PST - epublish
SO  - J Hepatocell Carcinoma. 2023 Sep 5;10:1435-1443. doi: 10.2147/JHC.S423684. 
      eCollection 2023.